Business Wire·Nov 11, 2026, 10:22 PM ET

PepGen Announces Pricing of $125 Million Public Offering

PepGen Inc. (Nasdaq: PEPG) priced a public offering of 25,000,000 shares of common stock at $5.00 per share.
The offering is expected to generate aggregate gross proceeds of $125 million before underwriting discounts, commissions, & expenses.
Underwriters received a 30-day option to purchase up to an additional 3,750,000 shares at the public offering price less discounts.
The offering is expected to close on or about November 13, 2026, subject to customary closing conditions.
Net proceeds will fund ongoing clinical development of product candidates, working capital, & other general corporate purposes.
Leerink Partners, Stifel, & Guggenheim Securities serve as joint bookrunning managers; Oppenheimer & Co. is the passive bookrunner; H.C. Wainwright & Co. is the lead manager.
The securities are offered pursuant to an effective Form S-3 shelf registration statement filed May 18, 2026, & declared effective May 21, 2026.
PepGen is a clinical-stage biotechnology company advancing PGN-EDODM1 for myotonic dystrophy type 1 using its Enhanced Delivery Oligonucleotide (EDO) technology.